Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China
HER2-mutated non-small lung cancer (NSCLC) in China represents a substantial patient population characterized by an unfavorable prognosis. However, at present, the main clinical treatment options are relatively limited. HER2 mutations in Chinese NSCLC (2019-2024) demonstrated 3.8%-5.6% prevalence vi...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-05-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748251347572 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849472314518798336 |
|---|---|
| author | Chang Liu MS Tao Li MD Xiaoran Cui MD Yahui Lv MS Min Liu MS Xin Zhou MS Fan Yang MS Yi Dong MS Ruixin Li MS Fan Zhang MD Tong Zhang MD Yi Hu MD |
| author_facet | Chang Liu MS Tao Li MD Xiaoran Cui MD Yahui Lv MS Min Liu MS Xin Zhou MS Fan Yang MS Yi Dong MS Ruixin Li MS Fan Zhang MD Tong Zhang MD Yi Hu MD |
| author_sort | Chang Liu MS |
| collection | DOAJ |
| description | HER2-mutated non-small lung cancer (NSCLC) in China represents a substantial patient population characterized by an unfavorable prognosis. However, at present, the main clinical treatment options are relatively limited. HER2 mutations in Chinese NSCLC (2019-2024) demonstrated 3.8%-5.6% prevalence via NGS, exceeding global baselines, with superior detection vs PCR (4.5% vs 3.1%). In addition, more attention was paid to molecular analysis and the detection rate of HER2 genomic alterations in NSCLC patients in eastern and northern China compared to other parts of China, which might be related to regional economic differences and geographic differences in lung cancer epidemiology. The evolving therapeutic landscape has established new-generation TKIs (pyrotinib) and antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-Dxd) as targeted strategies for HER2-mutant NSCLC. Despite late research initiation, China rapidly advanced from retrospective analyses to pioneering new drug trials. In general, the incidence of HER2-mutated NSCLC in the Chinese population seems to be higher than the world average, and there is a large number of missed HER2-mutated NSCLC patients in China. In this field, ADCs and novel TKIs are being developed and researched in spurts, and new drugs are moving from back-line therapy to front-line therapy, and from single-drug regimens to combination regimens. |
| format | Article |
| id | doaj-art-8c58cd734389492d9bb321d56eb4b110 |
| institution | Kabale University |
| issn | 1526-2359 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj-art-8c58cd734389492d9bb321d56eb4b1102025-08-20T03:24:34ZengSAGE PublishingCancer Control1526-23592025-05-013210.1177/10732748251347572Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in ChinaChang Liu MSTao Li MDXiaoran Cui MDYahui Lv MSMin Liu MSXin Zhou MSFan Yang MSYi Dong MSRuixin Li MSFan Zhang MDTong Zhang MDYi Hu MDHER2-mutated non-small lung cancer (NSCLC) in China represents a substantial patient population characterized by an unfavorable prognosis. However, at present, the main clinical treatment options are relatively limited. HER2 mutations in Chinese NSCLC (2019-2024) demonstrated 3.8%-5.6% prevalence via NGS, exceeding global baselines, with superior detection vs PCR (4.5% vs 3.1%). In addition, more attention was paid to molecular analysis and the detection rate of HER2 genomic alterations in NSCLC patients in eastern and northern China compared to other parts of China, which might be related to regional economic differences and geographic differences in lung cancer epidemiology. The evolving therapeutic landscape has established new-generation TKIs (pyrotinib) and antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-Dxd) as targeted strategies for HER2-mutant NSCLC. Despite late research initiation, China rapidly advanced from retrospective analyses to pioneering new drug trials. In general, the incidence of HER2-mutated NSCLC in the Chinese population seems to be higher than the world average, and there is a large number of missed HER2-mutated NSCLC patients in China. In this field, ADCs and novel TKIs are being developed and researched in spurts, and new drugs are moving from back-line therapy to front-line therapy, and from single-drug regimens to combination regimens.https://doi.org/10.1177/10732748251347572 |
| spellingShingle | Chang Liu MS Tao Li MD Xiaoran Cui MD Yahui Lv MS Min Liu MS Xin Zhou MS Fan Yang MS Yi Dong MS Ruixin Li MS Fan Zhang MD Tong Zhang MD Yi Hu MD Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China Cancer Control |
| title | Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China |
| title_full | Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China |
| title_fullStr | Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China |
| title_full_unstemmed | Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China |
| title_short | Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China |
| title_sort | advances and future perspectives of her2 mutations in non small lung cancer nsclc especially in china |
| url | https://doi.org/10.1177/10732748251347572 |
| work_keys_str_mv | AT changliums advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT taolimd advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT xiaorancuimd advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT yahuilvms advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT minliums advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT xinzhoums advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT fanyangms advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT yidongms advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT ruixinlims advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT fanzhangmd advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT tongzhangmd advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina AT yihumd advancesandfutureperspectivesofher2mutationsinnonsmalllungcancernsclcespeciallyinchina |